ELAN Q3 2019 Earnings — Elanco Animal Health Incorporated Revenue & Financial Results | Market Cap Arena

ELANElanco Animal Health Incorporated

$12B

Q3 2019 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$771M+1.3% YoY

Gross Profit

$360M46.7% margin

Operating Income

$98M12.7% margin

Net Income

$10M1.3% margin

EPS (Diluted)

$0.03

QoQ Revenue Growth

-1.3%

Cash Flow

Operating Cash Flow

$40M

Free Cash Flow

$5M

Stock-Based Comp.

$15M

Balance Sheet

Total Assets

$8.8B

Total Liabilities

$3.3B

Stockholders' Equity

$5.5B

Cash & Equivalents

$309M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$771M	$761M	+1.3%
Gross Profit	$360M	$343M	+5.1%
Operating Income	$98M	$105M	-6.4%
Net Income	$10M	$60M	-83.4%

Revenue Segments

Food Animal Ruminants And Swine

$266M35%

Companion Animal Disease Prevention

$208M27%

Food Animal Future Protein And Health

$192M25%

Companion Animal Therapeutics

$88M11%

Strategic Exits

$18M2%

Geographic Segments

UNITED STATES

$388M50%

Non-US

$383M50%